|Year : 2016 | Volume
| Issue : 3 | Page : 203-207
Ibrutinib: A comprehensive review of a promising drug
Akhil Kapoor1, Prakash Singh2, Surender Beniwal1, Mukesh Kumar Singhal1, Raj Kumar Nirban1, Harvindra Singh Kumar1
1 Department of Oncology, Acharya Tulsi Regional Cancer Treatment and Research Institute, Bikaner, Rajasthan, India
2 Department of Pathology, Sardar Patel Medical College and Associated Group of Hospitals, Bikaner, Rajasthan, India
|Date of Web Publication||9-May-2016|
Room No. 73, PG Boys Hostel, PBM Hospital Campus, Bikaner - 334 003, Rajasthan
Source of Support: None, Conflict of Interest: None
Ibrutinib is a recent Food and Drug Administration-approved drug for the treatment of lymphoid malignancies: mantle cell lymphoma and chronic lymphocytic leukemia (CLL). It is a Bruton's tyrosine kinase (BTK) inhibitor which increases the apoptotic susceptibility of malignant lymphocytes and also causes tissue redistribution of lymphocytes. Strong biological rationale makes BTK an ideal target for therapy of CLL and other B-cell malignancies. We are presenting a comprehensive review of this promising drug, highlighting its metabolism, safety profile, trials, and approved uses.
Keywords: Chronic lymphocytic leukemia, ibrutinib, mantle cell lymphoma
|How to cite this article:|
Kapoor A, Singh P, Beniwal S, Singhal MK, Nirban RK, Kumar HS. Ibrutinib: A comprehensive review of a promising drug. Clin Cancer Investig J 2016;5:203-7
|How to cite this URL:|
Kapoor A, Singh P, Beniwal S, Singhal MK, Nirban RK, Kumar HS. Ibrutinib: A comprehensive review of a promising drug. Clin Cancer Investig J [serial online] 2016 [cited 2020 Mar 31];5:203-7. Available from: http://www.ccij-online.org/text.asp?2016/5/3/203/182059
| Introduction|| |
Chronic lymphocytic leukemia (CLL) is a neoplastic disease characterized by the accumulation of a monoclonal population of small, mature-appearing CD5+ B lymphocytes in the blood, marrow, and lymphoid tissues. Although causes are unknown, genetic factors have been found to play a role. The median age at diagnosis is approximately 67 years and 90% are older than 50 years. Men are affected twice as often as women. At the time of diagnosis, more than 3/4th of the patients have lymphadenopathy and almost half shows splenomegaly. CLL patients show clonal chromosomal abnormalities, in which decreasing frequencies are del 13q14-23.1, trisomy 12, del 11q22.3-q23.1, del 6q21-q23, del 17p13.1, and 14q abnormalities. Strong biological rationale makes Bruton's tyrosine kinase (BTK) an ideal target for therapy of CLL and other B-cell malignancies.
Ibrutinib is a recently Food and Drug Administration (FDA) approved drug for the treatment of lymphoid malignancies: mantle cell lymphoma (MCL) and CLL. It is a BTK inhibitor which increases the apoptotic susceptibility of malignant lymphocytes and also causes tissue redistribution of lymphocytes. We are presenting a comprehensive review of this promising drug, highlighting its metabolism, safety profile, trials, and approved uses.
| Pathogenesis of Chronic Lymphocytic Leukemia|| |
To understand the basic functioning of ibrutinib, an insight into the pathogenesis of CLL is desirable. The basic defect in CLL is one of the cellular accumulations rather than proliferation, i.e., reduced apoptosis because of an imbalance in the favor of anti-apoptotic proteins such as B-cell lymphoma 2 (Bcl-2), Bcl-xl, myeloid cell leukemia 1, Bcl-2 associated athanogene-1, and low levels of the pro-apoptotic proteins bax or Bcl-xs. On the other hand, leukemic cells are also protected by the ability of marrow stromal cells, nurse-like cells, and follicular dendritic cells to inhibit spontaneous apoptosis of CLL cells, apparently through cell–cell contact and likely by the involvement of several chemokines such as stromal-derived factor 1 alpha (or CXCL13), CCL21, and/or CCL19.
B-cell receptor (BCR) plays a central role in the pathogenesis and progression of CLL. The BTK is at the crossroad of the BCR pathway. Microenvironment led activated BCR directs BTK to transduce signals to prevent apoptosis and promote leukemic cell survival.
The BCR is a CD79a/b membrane-bound immunoglobulin. Ligand binding to BCR recruits tyrosine kinases, including spleen tyrosine kinase and Src family kinases. This initial step translates into activation of a number of signal transduction molecules, including rat sarcoma viral oncogene homolog (RAF)-murine leukemia viral oncogene (RAF)-ERK/MAPK, PI3K, and BTK.
The BTK promotes the signaling mediators DAG/IP3 and thus activates protein kinase C (PKCβ). Increased PI3K causes a sustained calcium uptake and AKT/mTOR activation. Elevated calcium regulates the transcription factor, i.e., nuclear factor (NF) of activated T-cells, which activates prosurvival genes in B-cells. Ultimately, PKCβ leads to the recruitment of mucosa-associated lymphoid tissue lymphoma translocation gene 1 (MALT1) and B-cell CLL/lymphoma 10 protein (Bcl-10) into a multi-protein complex, and initiation of NF-kappa B signaling that ultimately causes increased survival, proliferation, and migration.
| Development of Ibrutinib|| |
Ibrutinib was originally developed by Celera Genomics for creating small molecules that irreversibly inhibit BTK. Later on, in April 2006, pharmacyclics acquired and continued Celera's small molecule BTK inhibitor discovery program, and chose PCI-32765 (ibrutinib) for further preclinical development based on the discovery of anti-lymphoma properties in vivo.
Ibrutinib is freely soluble in dimethyl sulfoxide, soluble in methanol, and practically insoluble in water. Its empirical formula is C25H24N6O2. Ibrutinib got US FDA approval for the treatment of MCL in November 13 and CLL in February 14.
| Mechanism of Action|| |
Strong biological rationale makes BTK an ideal target for therapy of CLL and other B-cell malignancies. Ibrutinib is a selective tyrosine kinase inhibitor that covalently and irreversibly binds BTK and consequently blocks survival and proliferation of CLL cells by blocking survival signals from the microenvironment including soluble factors (CD40 L, B-cell-activating factor of the tumor necrosis factor [TNF] family, interleukin-6 [IL-6], IL-4, and TNF-α). [Figure 1] shows the position of BTK in the BCR pathway. It also interrupts CXCL12- and CXCL13-mediated chemotaxis and stromal cell contact.
Besides anti-proliferative activity, ibrutinib induces the redistribution of tissue-resident CLL cells into the blood with rapid shrinkage of the lymph nodes. This interference with homing of leukemic cells causes prolonged accumulation of transcriptionally inert lymphocytes in peripheral blood. These lymphocytes have low mitotic index and simulate a state of anergy and quiescence.
| Drug Metabolism|| |
Ibrutinib is given by oral route. Food increases its absorption by two fold. The apparent volume of distribution at steady state is approximately 10,000 L. The prime route of elimination for ibrutinib is through metabolism. It is metabolized primarily by cytochrome P450, CYP3A, and to a minor extent by CYP2D6. PCI-45227 is the active metabolite which is 15 times less potent than ibrutinib. The half-life of ibrutinib is 4–6 h. Ibrutinib is eliminated primarily via feces after metabolism. Unchanged ibrutinib accounts for approximately 1% of the radiolabelled excretion product in feces and none in urine, with the remainder of dose being metabolite.
| Clinical Trials of Ibrutinib|| |
FDA approved ibrutinib for MCL in November, 2013. The approval was based on a study of 111 MCL patients whose disease had come back or was no longer responding to other treatments. In the phase II trial, labeled PCYC-1104, ibrutinib demonstrated an overall response rate (ORR) of 68%, including a complete response rate of 21%. Moreover, the median duration of response was 17.5 months. Based on these data, the FDA granted ibrutinib a breakthrough therapy designation and the eventual approval. FDA expanded the approval of ibrutinib in February 2014 to include the treatment of patients with CLL who have received at least one previous therapy, based on a single-arm clinical trial demonstrating a durable improvement in ORRs. The accelerated approval was supported specifically by 48 patients in the phase Ib/II PCYC-1102-CA study who received single-agent ibrutinib at 420 mg daily. In these selected patients, at a median 15.6-month follow-up, the ORR was 58.3% (all partial responses) with duration of response of up to 24.2 months, according to the FDA. The analysis used for the approval neither include data from 34 patients enrolled in the trial who received daily ibrutinib at 840 mg nor three patients with small lymphocytic lymphoma (SLL) who received the 420 mg dose. In a head-to-head comparison of two drugs for the treatment of relapsed CLL or SLL, ibrutinib statistically significantly outperformed atumumab as a second-line therapy. At a median follow-up of 9.4 months, ibrutinib significantly improved progression-free survival; the median duration was not reached in the ibrutinib group (with a rate of progression-free survival of 88% at 6 months), as compared with a median of 8.1 months in the atumumab group (hazard ratio for progression or death in the ibrutinib group, 0.22; P < 0.001). Ibrutinib also significantly improved the overall survival (hazard ratio for death, 0.43; P = 0.005). At 12 months, the overall survival rate was 90% in the ibrutinib group and 81% in the atumumab group. The ORR was significantly higher in the ibrutinib group than in the atumumab group (42.6% vs. 4.1%, P < 0.001).
| Side Effects of Ibrutinib|| |
Most important and serious side effects are hemorrhage, infections, myelosuppression, renal toxicity, and second primary malignancies (especially skin malignancy). The most commonly occurring adverse reactions (≥20%) were thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting, and anorexia. The most common ≥3 Grade nonhematological adverse reactions are pneumonia, abdominal pain, atrial fibrillation, diarrhea, fatigue, and skin infections.
In the treatment of CLL, the most commonly occurring adverse reactions (≥20%) in the clinical trial were thrombocytopenia (71%), diarrhea (63%), bruising (54%), neutropenia (54%), anemia (44%), upper respiratory tract infection (48%), fatigue (31%), musculoskeletal pain (27%), rash (27%), pyrexia (25%), constipation (23%), peripheral edema (23%), arthralgia (23%), nausea (21%), stomatitis (21%), sinusitis (21%), and dizziness (21%). The most common Grade 3 or 4 nonhematological adverse reactions (≥5%) were pneumonia (8%), hypertension (8%), atrial fibrillation (6.0%), sinusitis (6%), skin infection (6%), dehydration (6.0%), and musculoskeletal pain (6%). Treatment-emergent Grade 3 or 4 cytopenias were reported in 35% of patients.
In the treatment of MCL, the most commonly occurring adverse reactions (≥20%) in the clinical trial were thrombocytopenia (57%), diarrhea (51%), neutropenia (47%), anemia (41%), fatigue (41%), musculoskeletal pain (37%), peripheral edema (35%), upper respiratory tract infection (34%), nausea (31%), bruising (30%), dyspnea (27%), constipation (25%), rash (25%), abdominal pain (24%), vomiting (23%), and decreased appetite (21%). The most common Grade 3 or 4 nonhematological adverse reactions (≥5%) were pneumonia (7%), abdominal pain (5%), atrial fibrillation (5.4%), diarrhea (5%), fatigue (5%), and skin infections (5%). Treatment-emergent Grade 3 or 4 cytopenias were reported in 41% of the patients.
| Precautions|| |
Ibrutinib should be taken by mouth with a glass of water. It should be swallowed as a whole. Opening, breaking, or chewing before swallowing are discouraged. Food or drink containing grapefruit or Seville oranges should be avoided while taking ibrutinib. The patient is encouraged to drink extra fluids. As ibrutinib is chiefly metabolized by CYP 3A, drugs affecting CYP3A will affect its functionality. Its toxicity increases in hepatic dysfunction. Treating doctors should be more cautious in a sense, not to unnecessarily discontinue ibrutinib in the background of persistent lymphocytosis as these lymphocytes are transcriptionally inert.
Ibrutinib should not be used if the patient is allergic to any ingredient in ibrutinib, pregnancy and breast feeding, liver problems, kidney problems, high blood pressure, blood problems, or bleeding problems, or if you have had recent surgery or plan to have surgery.
| Food and Drug Administration-Approved Dosage, Indications, and Modifications|| |
- About 560 mg orally OD for MCL patients who have received at least one prior therapy 
- About 420 mg orally OD for CLL patients who have received at least one prior therapy.
If there is mild-to-moderate renal impairment (Cr clearance >25 mL/min), ibrutinib exposure is not altered. In case of severe renal impairment (Cr clearance <25 mL/min), exact guidelines are not available due to lack of studies in this population.
Dose adjustment may be required in case of hepatic impairment; however, no specific guidelines have been suggested. Caution is recommended.
Dose modifications for adverse reactions: If the patient suffers from Grade 3 or higher toxicities, ibrutinib should be interrupted. The recommended schedule for restarting ibrutinib is shown in [Table 1].
|Table 1: Dose modification recommended for restarting the treatment after Grade 3 or higher toxicity|
Click here to view
Dose modifications for use with CYP4503A inhibitors
Concomitant use of strong CYP450 3A inhibitors is not recommended. For short-term use (treatment for 7 days or less) of strong CYP450 3A inhibitors (e.g., anti-fungals and antibiotics), interruption of the therapy is considered until the CYP450 3A inhibitor is no longer needed. Reduce dose to 140 mg if a moderate CYP450 3A inhibitor must be used.
| Conclusion|| |
Ibrutinib is an effective drug for B-cell malignancies such as MCL and CLL. OD oral dosing is convenient for the patients and also more compliant. Given the promise for B-cells, ibrutinib in future may be effective for other lymphoid malignancies. Further studies are needed to evaluate long-term side effects and modifications in liver disease patients.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-15.
Ries L, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, et al
. SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute; 2008.
Klein U, Dalla-Favera R. New insights into the pathogenesis of chronic lymphocytic leukemia. Semin Cancer Biol 2010;20:377-83.
García-Muñoz R, Galiacho VR, Llorente L. Immunological aspects in chronic lymphocytic leukemia (CLL) development. Ann Hematol 2012;91:981-96.
Deaglio S, Malavasi F. Chronic lymphocytic leukemia microenvironment: Shifting the balance from apoptosis to proliferation. Haematologica 2009;94:752-6.
Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: Revelations from the B-cell receptor. Blood 2004;103:4389-95.
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al.
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507-16.
O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, et al.
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014;15:48-58.
Niemann CU, Wiestner A. B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol 2013;23:410-21.
Darzentas N, Stamatopoulos K. The significance of stereotyped B-cell receptors in chronic lymphocytic leukemia. Hematol Oncol Clin North Am 2013;27:237-50.
Cheson BD, Byrd JC, Rai KR, Kay NE, O'Brien SM, Flinn IW, et al.
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012;30:2820-2.
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al.
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32-42.
Winer ES, Ingham RR, Castillo JJ. PCI-32765: A novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs 2012;21:355-61.
Byrd J, Blum K, Burger J, Sharman JP, Furman RR, Flinn IW, et al
. Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study. J Clin Oncol 2011;29:6508.
Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, et al.
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro
and in vivo
. Blood 2012;119:1182-9.
Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, et al.
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371:213-23.
Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, et al
. The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients. ASH Ann Meet Abstr 2012;120:187.
Jaglowski SM, Jones JA, Flynn JM, Andritsos LA, Maddocks KJ, Blum KA, et al
. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. ASCO Meet Abstr 2012;30 Suppl 15:6508.
Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, et al.
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010;107:13075-80.
Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, et al.
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011;117:6287-96.
de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, et al.
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012;119:2590-4.
Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, et al.
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 2014;123:1810-7.
Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Ciardullo C, et al.
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013;121:1403-12.
Advani R, Sharman J, Smith S, Buggy JJ, Smith SM, Boyd TE, et al
. The Btk inhibitor PCI-32765 is highly active and well tolerated in patients with relapsed/refractory B cell malignancies: Final results from a phase I study. Ann Oncol 2011;22 Suppl 4:135.
Imbruvica [Package insert]. Sunnyvale, California: Pharmacyclics Inc.; 2016.